

Oncology Today with Dr Neil Love: Management of Localized Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- How did the incidence of disease recurrence in the central nervous system (CNS) compare for patients who received osimertinib versus placebo in the ADAURA trial?**

 - The rate of disease recurrence in the CNS was similar between arms
 - The rate of disease recurrence in the CNS was slightly increased with osimertinib
 - The rate of disease recurrence in the CNS was significantly decreased with osimertinib**
- What adverse event (AE) data were reported with atezolizumab from the updated analysis of the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for completely resected NSCLC?**

 - The incidence of grade 3/4 AEs was >30%
 - Treatment-related grade 5 AEs occurred in 0.8% of patients**
 - AEs led to treatment discontinuation in 12% of patients
 - AEs of special interest required corticosteroids in 35% of patients
- Which of the following results has been reported from the CheckMate 816 trial evaluating neoadjuvant nivolumab combined with chemotherapy versus chemotherapy alone for patients with newly diagnosed Stage IB-IIIA non-small cell lung cancer (NSCLC)?**

 - The addition of nivolumab to chemotherapy significantly improved the pathologic complete response (pCR) rate and overall survival compared to chemotherapy alone**
 - The addition of nivolumab to chemotherapy did not significantly improve pCR rate or overall survival compared to chemotherapy alone
- Among patients enrolled in the IMpower010 trial whose tumors had PD-L1 expression $\geq 1\%$, which of the following disease-free survival (DFS) results was reported with atezolizumab in a subgroup analysis?**

 - DFS improved regardless of EGFR mutation status**
 - DFS improved regardless of current or former smoking status
 - DFS was longest among patients who received cisplatin/gemcitabine compared to other chemotherapy regimens
 - DFS was longest among patients with squamous histology compared to nonsquamous histology
- What DFS results have been reported with pembrolizumab in a subgroup analysis of the Phase III PEARLS/KEYNOTE-091 study of pembrolizumab as adjuvant therapy for Stage IB to IIIA NSCLC?**

 - Patients with Stage IIIA disease had the longest DFS compared to other stages of disease
 - PD-L1 TPS $\geq 50\%$ was associated with the longest DFS compared to lower TPS
 - Current smokers had the longest DFS compared to former and never smokers**
 - DFS was improved regardless of receipt of adjuvant chemotherapy